CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer
Frederik Marmé, Wiebke Werft, Anne Walter et al. · Breast Cancer Research and Treatment · 2011
Cited by 23 works. doi:10.1007/s10549-011-1759-9
Authors
- Frederik Marmé
- Wiebke Werft
- Anne Walter
- Sascha Keller
- Xiaoli Wang
- Axel Benner
- Barbara Burwinkel
- Hans‐Peter Sinn
- Sarah Hug
- Christof Sohn
- Niko P. Bretz
- Gerhard Moldenhauer
- Christian Rupp
- Anne-Kathleen Rupp
- Mikhail Yu Biakhov
- Alberto Bottini
- Kay Friedrichs
- В. А. Хайленко
- G. Manikhas
- Amparo Ruı́z
References
- New Guidelines to Evaluate the Response to Treatment in Solid Tumors
- Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast Cancer
- Clinical Course of Breast Cancer Patients With Complete Pathologic Primary Tumor and Axillary Lymph Node Response to Doxorubicin-Based Neoadjuvant Chemotherapy
- Calreticulin exposure dictates the immunogenicity of cancer cell death
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27
- Immunological aspects of cancer chemotherapy
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors
- Fully conditional specification in multivariate imputation